SynCardia Named "Arizona Bioscience Company of the Year"
Total Artificial Heart Manufacturer Honored by Arizona BioIndustry Association for "Doing the Most to Transform the World during the Last 12 Months"
TUCSON, Ariz. – Oct. 18, 2011 – On Oct. 13, SynCardia Systems, Inc., manufacturer of the world's only FDA, Health Canada and CE approved Total Artificial Heart, was named "Arizona Bioscience Company of the Year" by the Arizona BioIndustry Association (AZBio).
"The Arizona Bioscience Company of the Year Award recognizes the for-profit bioscience company whose Arizona-based operations did the most to transform the world during the last 12 months" said AZBio CEO Joan Koerber-Walker. "SynCardia makes it possible for patients awaiting donor hearts to not only survive the wait but also to do so with flexibility and mobility, a feat of biomedical engineering that is world-changing for these patients."
SynCardia designed, developed, and introduced the Freedom® portable driver, the world's first wearable power supply for the SynCardia temporary Total Artificial Heart. For the first time in U.S. history, stable patients without human hearts are being discharged from the hospital to wait for a matching donor heart at home using the Freedom portable driver to power their Total Artificial Hearts. Weighing 13.5 pounds, the Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.
Prior to the development of the Freedom driver, U.S. Total Artificial Heart patients were confined to the hospital for months, sometimes years, while they waited for a heart transplant because the only FDA-approved driver for powering the Total Artificial Heart is hospital-based "Big Blue" which weighs 418 pounds.
Life for a stable Total Artificial Heart patient confined to the hospital is emotionally, physically and financially draining for them, their family and the hospital. As wait times for a heart transplant continue to lengthen, the ability to discharge stable patients home is critical for both the patient and the hospital. Recovery at home improves patient quality of life while eliminating most in-hospital costs for this portion of patient care.
The other two finalists for the award were Calimmune, Inc., which is developing innovative cell-based therapies for treating HIV, and VisionGate, which has developed an automated 3D cell imaging platform to help detect lung cancer sooner.
AZBio is the state affiliate of the Biotechnology Industry Organization (BIO), the preeminent national association for biotechnology companies, and of AdvaMed, the largest association representing manufacturers of medical devices, diagnostic products and medical information systems.
CAUTION – The Freedom® portable driver is an investigational device, limited by United States law to investigational use.
About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the temporary Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.
Janelle Drumwright, email@example.com, (520) 547-7463